Fibrogen Inc (NASDAQ:FGEN)’s Trend Up, Especially After Decreased Shorts

May 26, 2018 - By Maria Brooks

The stock of Fibrogen Inc (NASDAQ:FGEN) registered a decrease of 1.16% in short interest. FGEN’s total short interest was 2.77M shares in May as published by FINRA. Its down 1.16% from 2.80M shares, reported previously. With 293,100 shares average volume, it will take short sellers 9 days to cover their FGEN’s short positions.

The stock increased 0.39% or $0.2 during the last trading session, reaching $51.65. About 273,000 shares traded. FibroGen, Inc. (NASDAQ:FGEN) has risen 78.19% since May 26, 2017 and is uptrending. It has outperformed by 66.64% the S&P500.

FibroGen, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes therapeutic agents to treat serious unmet medical needs in the United States. The company has market cap of $4.31 billion. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; Pamrevlumab, a human-monoclonal antibody that inhibits the activity of connective tissue growth factor, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and Duchenne muscular dystrophy; and FG-5200 for the treatment of corneal blindness resulting from partial thickness corneal damage. It currently has negative earnings. It has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB.

FibroGen, Inc. (NASDAQ:FGEN) Ratings Coverage

Among 2 analysts covering FibroGen (NASDAQ:FGEN), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. FibroGen had 3 analyst reports since February 28, 2018 according to SRatingsIntel. The firm earned “Buy” rating on Wednesday, February 28 by Leerink Swann. The stock of FibroGen, Inc. (NASDAQ:FGEN) has “Buy” rating given on Tuesday, May 15 by Mizuho. Mizuho maintained FibroGen, Inc. (NASDAQ:FGEN) rating on Thursday, March 29. Mizuho has “Hold” rating and $6100 target.

More notable recent FibroGen, Inc. (NASDAQ:FGEN) news were published by: Globenewswire.com which released: “FibroGen Reports First Quarter 2018 Financial Results” on May 09, 2018, also Nasdaq.com with their article: “FibroGen to Report First Quarter 2018 Financial Results on Wednesday, May 9, 2018” published on May 02, 2018, Seekingalpha.com published: “FibroGen’s (FGEN) CEO Tom Neff on Q1 2018 Results – Earnings Call Transcript” on May 10, 2018. More interesting news about FibroGen, Inc. (NASDAQ:FGEN) were released by: Seekingalpha.com and their article: “FibroGen’s pamrevlumab shows treatment effect in mid-stage IPF study; shares up 2% after hours” published on May 21, 2018 as well as Streetinsider.com‘s news article titled: “FibroGen (FGEN) Highlights Latest Data from PRAISE Phase 2b Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis” with publication date: May 21, 2018.

FibroGen, Inc. (NASDAQ:FGEN) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: